期刊论文详细信息
BMC Cancer
3D-image-guided HDR-brachytherapy versus 2D HDR - brachytherapy after external beam radiotherapy for early T-stage nasopharyngeal carcinoma
YuFeng Ren5  QuanCheng Zhao1  Hui Liu5  YingJuan Huang3  ZhenYu Wang4  XinPing Cao5  Bin S Teh2  BiXiu Wen4 
[1] Department of Neurosurgery, Binzhou People’s hospital, Binzhou P.R.China
[2] Department of Radiation Oncology, the Methodist Hospital, 6565 Fannin, Houston, Texas 77030, USA
[3] Department of Traditional Chinese medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, P.R.China
[4] Department of Radiation Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, P.R.China
[5] State Key Laboratory of Oncology in Southern China, Department of Radiation Oncology, Cancer Center, Sun Yat-sen University, Guangzhou 510060, P.R.China
关键词: Local control;    Brachytherapy;    3D-image-guided;    Radiotherapy;    Nasopharyngeal carcinoma;   
Others  :  1117979
DOI  :  10.1186/1471-2407-14-894
 received in 2014-05-27, accepted in 2014-11-17,  发布年份 2014
PDF
【 摘 要 】

Background

Two-dimensional high-dose-rate brachytherapy (2D-HDR-BT) is an effective method of dose escalation for local tumor control in early T-stage nasopharyngeal carcinoma (NPC). Treatment outcomes for 3D-image-guided high-dose-rate brachytherapy (3D-image-guided-HDR-BT) after external beam radiotherapy (ERT) have not been examined in early T-stage NPC patients. The current study was designed to evaluate whether addition of 3D-HDR-BT to ERT showed further improvement in treatment outcomes in patients with early T-stage NPC when compared to 2D-HDR-BT after ERT.

Methods

The current study retrospectively analyzed and compared treatment outcomes for patients with nonmetastatic stage T1-2b NPC treated with 2D-HDR-BT (n =101) or 3D-HDR-BT (n =118) after ERT. Patients in both groups were treated with ERT at a mean dose of 60 Gy and a brachytherapy dose of 12Gy (8 ~ 20Gy), 2.5 ~ 5Gy per fraction under local anesthesia.

Results

Compared to patients treated with 2D-HDR-BT after ERT, patients treated with 3D-HDR-BT after ERT showed improvement in five-year actuarial local control survival rates (p = 0.024), local/regional relapse-free survival rates (p = 0.038), and disease-free survival rates (p = 0.021). Multivariate analysis showed that NPC patients treated with 3D-HDR-BT had improved local control survival (p = 0.042). The incidence rates of acute or chronic complications were similar between two groups.

Conclusions

The current study showed that 3D-image-guided HDR-BT after ERT was an effective treatment modality for patients with stage T1-2 NPC with acceptable complications. The improvement in local tumor control and disease free survival is likely due to improved conformal dose distributions.

【 授权许可】

   
2014 Ren et al.; licensee BioMed Central Ltd.

【 预 览 】
附件列表
Files Size Format View
20150206014417236.pdf 756KB PDF download
Figure 5. 48KB Image download
Figure 4. 37KB Image download
Figure 3. 84KB Image download
Figure 2. 68KB Image download
Figure 1. 71KB Image download
【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】
  • [1]Wu F, Wang R, Lu H, Wei B, Feng G, Li G, Liu M, Yan H, Zhu J, Zhang Y, Hu K: Concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: treatment outcomes of a prospective, multicentric clinical study. Radiother Oncol 2014, 112:106-111.
  • [2]Wang WY, Twu CW, Chen HH, Wang WY, Twu CW, Chen HH, Jiang RS, Wu CT, Liang KL, Shih YT, Chen CC, Lin PJ, Liu YC, Lin JC: Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levels. Cancer 2013, 119:963-970.
  • [3]Teo PM, Leung SF, Lee WY, Zee B: Intracavitary brachytherapy significantly enhances local control of early T-stage nasopharyngeal carcinoma: the existence of a dose-tumor-control relationship above conventional tumoricidal dose. Int J Radiat Oncol Biol Phys 2000, 46:445-458.
  • [4]Leung TW, Wong VY, Sze WK, Lui CM, Tung SY: High-dose-rate intracavitary brachytherapy boost for early T stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2008, 70:361-367.
  • [5]Levendag PC, Keskin-Cambay F, de Pan C, Idzes M, Wildeman MA, Noever I, Kolkman-Deurloo IK, Al-Mamgani A, El-Gantiry M, Rosenblatt E, Teguh DN: Local control in advanced cancer of the nasopharynx: is a boost dose by endocavitary brachytherapy of prognostic significance? Brachytherapy 2013, 12:84-89.
  • [6]Madan R, Pathy S, Subramani V, Sharma S, Mohanti BK, Chander S, Thulkar S, Kumar L, Dadhwal V: Comparative evaluation of two-dimensional radiography and three dimensional computed tomography based dose-volume parameters for high-dose-rate intracavitary brachytherapy of cervical cancer: a prospective study. Asian Pac J Cancer Prev 2014, 15:4717-4721.
  • [7]Oden J, Toma-Dasu I, Yu CX, Feigenberg SJ, Regine WF, Mutaf YD: Dosimetric comparison between intra-cavitary breast brachytherapy techniques for accelerated partial breast irradiation and a novel stereotactic radiotherapy device for breast cancer: GammaPod. Phys Med Biol 2013, 58:4409-4421.
  • [8]Marina O, Gustafson GS, Kestin LL, Brabbins DS, Chen PY, Ye H, Martinez AA, Ghilezan MI, Wallace M, Krauss DJ: Comparison of dose-escalated, image-guided radiotherapy vs. dose-escalated, high-dose-rate brachytherapy boost in a modern cohort of intermediate-risk prostate cancer patients. Brachytherapy 2014, 13:59-67.
  • [9]Ren YF, Cao XP, Xu J, Ye WJ, Gao YH, Teh BS, Wen BX: 3D-image-guided high-dose-rate intracavitary brachytherapy for salvage treatment of locally persistent nasopharyngeal carcinoma. Radiat Oncol 2013, 8:165. BioMed Central Full Text
  • [10]Greene FL, Page DL, Fleming ID, Al. E: AJCC cancer staging handbook from the AJCC cancer staging manual. 6th edition. New York: Springer; 2002.
  • [11]Lei C, Chao-Su H, Chen L, Hu CS, Chen XZ, Hu GQ, Cheng ZB, Sun Y, Li WX, Chen YY, Xie FY, Liang SB, Chen Y, Xu TT, Li B, Long GX, Wang SY, Zheng BM, Guo Y, Sun Y, Mao YP, Tang LL, Chen YM, Liu MZ, Ma J: Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol 2012, 13(2):163-171.
  • [12]Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
  • [13]Peto R, Pike MC, Armitage P, Et A: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1958, 35:1-39.
  • [14]Cox DR: Regression models and life tables. J R Stat Soc B 1972, 34:187-220.
  • [15]Li JX, Lu TX, Huang Y, Han F: Clinical characteristics of recurrent nasopharyngeal carcinoma in high-incidence area. ScientificWorldJournal 2012, 2012:719754.
  • [16]Sun X, Su S, Chen C, Han F, Zhao C, Xiao W, Deng X, Huang S, Lin C, Lu T: Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Radiother Oncol 2014, 110:398-403.
  • [17]Xiao WW, Huang SM, Han F, Wu SX, Lu LX, Lin CG, Deng XW, Lu TX, Cui NJ, Zhao C: Local control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy: long-term results of a phase 2 study. Cancer 2011, 117:1874-1883.
  • [18]Wang J, Shi M, Hsia Y, Luo S, Zhao L, Xu M, Xiao F, Fu X, Li J, Zhou B, Long X: Failure patterns and survival in patients with nasopharyngeal carcinoma treated with intensity modulated radiation in Northwest China: a pilot study. Radiat Oncol 2012, 7:2. BioMed Central Full Text
  • [19]Osewski W, Dolla L, Radwan M, Szlag M, Rutkowski R, Smolinska B, Slosarek K: Clinical examples of 3D dose distribution reconstruction, based on the actual MLC leaves movement, for dynamic treatment techniques. Rep Pract Oncol Radiother 2014, 19:420-427.
  • [20]Wan XB, Jiang R, Xie FY, Qi ZY, Li AJ, Ye WJ, Hua YJ, Zhu YL, Zou X, Guo L, Mai HQ, Guo X, Hong MH, Chen MY: Endoscope-guided interstitial intensity-modulated brachytherapy and intracavitary brachytherapy as boost radiation for primary early T stage nasopharyngeal carcinoma. PLoS One 2014, 9:90048.
  • [21]Ren YF, Gao YH, Cao XP, Ye WJ, Teh BS: 3D-CT implanted interstitial brachytherapy for T2b nasopharyngeal carcinoma. Radiat Oncol 2010, 5:113. BioMed Central Full Text
  • [22]Leung TW, Tung SY, Wong VY, Sze WK, Lui CM, Wong FC, Lee AS, O.SK: Nasopharyngeal intracavitary brachytherapy: the controversy of T2b disease. Cancer 2005, 104:1648-1655.
  • [23]Rosenblatt E, Abdel-Wahab M, El-Gantiry M, Elattar I, Bourque JM, Afiane M, Benjaafar N, Abubaker S, Chansilpa Y, Vikram B, Levendag P: Brachytherapy boost in loco – regionally advanced nasopharyngeal carcinoma: a prospective randomized trial ofthe International Atomic Energy Agency. Radiat Oncol 2014, 9:67. BioMed Central Full Text
  • [24]Leibel SA, Scott CB, Mohiuddin M, Et A: The effect of local-regional control on distant metastatic dissemination in carcinoma of the head and neck: results of an analysis from the RTOG head and neck database. Int J Radiat Oncol Biol Phys 1991, 21:549-556.
  • [25]Chang JT, Chan SC, Yen TC, Liao CT, Lin CY, Lin KJ, Chen IH, Wang HM, Chang YC, Chen TM, Kang CJ, Ng SH: Nasopharyngeal carcinoma staging by (18) F-fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys 2005, 62:501-507.
  • [26]Huang HI, Chan KT, Shu CH, Ho CY: T4-locally advanced nasopharyngeal carcinoma: prognostic influence of cranial nerve involvement in different radiotherapy techniques. Sci World J 2013, 2013:439073.
  文献评价指标  
  下载次数:29次 浏览次数:9次